News

Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA

(Oxford, UK and Conshohocken, US, 26 October 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, today announces that Chief Executive Officer Andrew Hotchkiss has been appointed to the Board of The BioIndustry Association (BIA).

The BIA is the trade association for innovative life sciences in the UK. The BIA’s goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

Andrew Hotchkiss, CEO of Immunocore, added: “The BIA plays a crucial role in representing the interests of some of the UK’s most promising companies and championing the UK as a leader in the research, development and commercialisation of cutting edge biotechnologies. It is an honour to be elected to the Board and I look forward to working alongside my fellow Board members as well as the BIA’s diverse membership in order to help further develop and promote the UK life sciences sector.”

Please click on the link below to download the full Press Release:

Download press release
Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA